SHAREHOLDERS' EQUITY - Narrative (Details)					3 Months Ended		9 Months Ended		58 Months Ended
	Apr. 26, 2023 shares	Nov. 17, 2022 USD ($) $ / shares shares	Jul. 18, 2021	Feb. 04, 2020 USD ($) sales_agent	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Oct. 11, 2023 shares	Oct. 10, 2023 shares	Mar. 31, 2023 shares	Aug. 02, 2022 USD ($)	Aug. 01, 2022 USD ($)	Aug. 31, 2021 USD ($)	Jul. 28, 2021 USD ($)	May 26, 2021 USD ($)	Mar. 04, 2019 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized (in shares) | shares					75,000,000		75,000,000		75,000,000	75,000,000	40,000,000	40,000,000
Repurchase authorized amount															$ 20,000,000	$ 20,000,000
Cancellation of treasury stock (in shares) | shares	2,339,512
Public Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Number of shares sold (in shares) | shares		2,534,436
Par value, common stock (in usd per share) | $ / shares		$ 18.15
Gross proceeds received (in thousands)		$ 46,000,000
Net proceeds received		$ 44,100,000
Equity ATM Program
Subsidiary or Equity Method Investee [Line Items]
Number of shares sold (in shares) | shares					3,036,234	3,264,878	6,663,692	6,909,446	23,276,814
Gross proceeds received (in thousands)					$ 66,549,000	$ 58,324,000	$ 134,965,000	$ 131,990,000	$ 479,600,000
Net proceeds received					$ 65,551,000	$ 57,449,000	$ 132,941,000	$ 130,010,000	$ 472,000,000
Maximum consideration threshold				$ 100,000,000									$ 650,000,000	$ 250,000,000			$ 250,000,000	$ 50,000,000
Number of additional sales agents | sales_agent				2
Gross sales commission percentage																	1.50%	2.00%
Weighted average price per share (in usd per share) | $ / shares					$ 21.92	$ 17.86	$ 20.25	$ 19.10	$ 20.61
Available under the Equity ATM Program					$ 170,400,000		$ 170,400,000		$ 170,400,000
2010 Plan | Restricted Stock
Subsidiary or Equity Method Investee [Line Items]
Right to grant period			10 years